154 related articles for article (PubMed ID: 35064272)
1. Predictive performance of next generation human physiologically based kinetic (PBK) models based on in vitro and in silico input data.
Punt A; Louisse J; Beekmann K; Pinckaers N; Fabian E; Van Ravenzwaay B; Carmichael PL; Sorrell I; Moxon TE
ALTEX; 2022; 39(2):221–234. PubMed ID: 35064272
[TBL] [Abstract][Full Text] [Related]
2. Predictive Performance of Next Generation Physiologically Based Kinetic (PBK) Model Predictions in Rats Based on In Vitro and In Silico Input Data.
Punt A; Louisse J; Pinckaers N; Fabian E; van Ravenzwaay B
Toxicol Sci; 2022 Feb; 186(1):18-28. PubMed ID: 34927682
[TBL] [Abstract][Full Text] [Related]
3. Impact of in vitro experimental variation in kinetic parameters on physiologically based kinetic (PBK) model simulations.
Punt A; Bos P; Hakkert B; Louisse J
ALTEX; 2023; 40(2):237–247. PubMed ID: 35901496
[TBL] [Abstract][Full Text] [Related]
4. PBK modelling of topical application and characterisation of the uncertainty of C
Li H; Reynolds J; Sorrell I; Sheffield D; Pendlington R; Cubberley R; Nicol B
Toxicol Appl Pharmacol; 2022 May; 442():115992. PubMed ID: 35346730
[TBL] [Abstract][Full Text] [Related]
5. Systematic evaluation of high-throughput PBK modelling strategies for the prediction of intravenous and oral pharmacokinetics in humans.
Geci R; Gadaleta D; de Lomana MG; Ortega-Vallbona R; Colombo E; Serrano-Candelas E; Paini A; Kuepfer L; Schaller S
Arch Toxicol; 2024 May; ():. PubMed ID: 38722347
[TBL] [Abstract][Full Text] [Related]
6. Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment.
Najjar A; Punt A; Wambaugh J; Paini A; Ellison C; Fragki S; Bianchi E; Zhang F; Westerhout J; Mueller D; Li H; Shi Q; Gant TW; Botham P; Bars R; Piersma A; van Ravenzwaay B; Kramer NI
Arch Toxicol; 2022 Dec; 96(12):3407-3419. PubMed ID: 36063173
[TBL] [Abstract][Full Text] [Related]
7. Next generation physiologically based kinetic (NG-PBK) models in support of regulatory decision making.
Paini A; Leonard JA; Joossens E; Bessems JGM; Desalegn A; Dorne JL; Gosling JP; Heringa MB; Klaric M; Kliment T; Kramer NI; Loizou G; Louisse J; Lumen A; Madden JC; Patterson EA; Proença S; Punt A; Setzer RW; Suciu N; Troutman J; Yoon M; Worth A; Tan YM
Comput Toxicol; 2019 Feb; 9():61-72. PubMed ID: 31008414
[TBL] [Abstract][Full Text] [Related]
8. Development of a Combined In Vitro Physiologically Based Kinetic (PBK) and Monte Carlo Modelling Approach to Predict Interindividual Human Variation in Phenol-Induced Developmental Toxicity.
Strikwold M; Spenkelink B; Woutersen RA; Rietjens IMCM; Punt A
Toxicol Sci; 2017 Jun; 157(2):365-376. PubMed ID: 28498972
[TBL] [Abstract][Full Text] [Related]
9. A physiologically based kinetic modeling of ethyl tert-butyl ether in humans-An illustrative application of quantitative structure-property relationship and Monte Carlo simulation.
Watanabe-Matsumoto S; Yoshida K; Meiseki Y; Ishida S; Hirose A; Yamada T
J Toxicol Sci; 2022; 47(2):77-87. PubMed ID: 35110473
[TBL] [Abstract][Full Text] [Related]
10. Combining in vitro embryotoxicity data with physiologically based kinetic (PBK) modelling to define in vivo dose-response curves for developmental toxicity of phenol in rat and human.
Strikwold M; Spenkelink B; Woutersen RA; Rietjens IM; Punt A
Arch Toxicol; 2013 Sep; 87(9):1709-23. PubMed ID: 23943240
[TBL] [Abstract][Full Text] [Related]
11. Use of Physiologically-Based Kinetics Modelling to Reliably Predict Internal Concentrations of the UV Filter, Homosalate, After Repeated Oral and Topical Application.
Najjar A; Schepky A; Krueger CT; Dent M; Cable S; Li H; Grégoire S; Roussel L; Noel-Voisin A; Hewitt NJ; Cardamone E
Front Pharmacol; 2021; 12():802514. PubMed ID: 35058784
[TBL] [Abstract][Full Text] [Related]
12. Application of partition coefficient methods to predict tissue:plasma affinities in common farm animals: Influence of ionisation state.
Lautz LS; Dorne JCM; Punt A
Toxicol Lett; 2024 Jun; ():. PubMed ID: 38925423
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the predictive capacity of a physiologically based kinetic model using a read-across approach.
Paini A; Worth A; Kulkarni S; Ebbrell D; Madden J
Comput Toxicol; 2021 May; 18():100159. PubMed ID: 34027243
[TBL] [Abstract][Full Text] [Related]
14. A generic avian physiologically-based kinetic (PBK) model and its application in three bird species.
Baier V; Paini A; Schaller S; Scanes CG; Bone AJ; Ebeling M; Preuss TG; Witt J; Heckmann D
Environ Int; 2022 Nov; 169():107547. PubMed ID: 36179644
[TBL] [Abstract][Full Text] [Related]
15. ADME characterization and PBK model development of 3 highly protein-bound UV filters through topical application.
Li H; Bunglawala F; Hewitt NJ; Pendlington R; Cubberley R; Nicol B; Spriggs S; Baltazar M; Cable S; Dent M
Toxicol Sci; 2023 Oct; 196(1):1-15. PubMed ID: 37584694
[TBL] [Abstract][Full Text] [Related]
16. An open source physiologically based kinetic model for the chicken (Gallus gallus domesticus): Calibration and validation for the prediction residues in tissues and eggs.
Lautz LS; Nebbia C; Hoeks S; Oldenkamp R; Hendriks AJ; Ragas AMJ; Dorne JLCM
Environ Int; 2020 Mar; 136():105488. PubMed ID: 31991240
[TBL] [Abstract][Full Text] [Related]
17. Prediction of dose-dependent in vivo acetylcholinesterase inhibition by profenofos in rats and humans using physiologically based kinetic (PBK) modeling-facilitated reverse dosimetry.
Omwenga I; Zhao S; Kanja L; Mol H; Rietjens IMCM; Louisse J
Arch Toxicol; 2021 Apr; 95(4):1287-1301. PubMed ID: 33651127
[TBL] [Abstract][Full Text] [Related]
18. Predicting points of departure for risk assessment based on in vitro cytotoxicity data and physiologically based kinetic (PBK) modeling: The case of kidney toxicity induced by aristolochic acid I.
Abdullah R; Alhusainy W; Woutersen J; Rietjens IM; Punt A
Food Chem Toxicol; 2016 Jun; 92():104-16. PubMed ID: 27016491
[TBL] [Abstract][Full Text] [Related]
19. Applicability of generic PBK modelling in chemical hazard assessment: A case study with IndusChemFate.
Fragki S; Piersma AH; Westerhout J; Kienhuis A; Kramer NI; Zeilmaker MJ
Regul Toxicol Pharmacol; 2022 Dec; 136():105267. PubMed ID: 36367522
[TBL] [Abstract][Full Text] [Related]
20. Integrating in vitro chemical transplacental passage into a generic PBK model: A QIVIVE approach.
Fragki S; Hoogenveen R; van Oostrom C; Schwillens P; Piersma AH; Zeilmaker MJ
Toxicology; 2022 Jan; 465():153060. PubMed ID: 34871708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
